Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis
In brief
rhBMP-2 had fewer infections but nearly 10-fold higher odds of swelling
Across seven studies of 808 patients, rhBMP-2 was associated with 80% lower odds of infection than iliac crest bone graft, but nearly 10-fold higher odds of postoperative swelling. Researchers found no clear differences in graft failure, wound breakdown or fistula; low-certainty evidence, mostly observational, leaves the safety comparison unsettled.
- Journal
- The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association (Q1)
- Published
- 17 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Abdulla Alhamdan, Efthimios Demetriou, Mohammad Almeer, Christoforos Demosthenous, Hiba Nura Miyir, Dino Zammit
- PMID
- 43042568
- DOI
- 10.1177/10556656261507944
Why clinicians should know about it
- Picked for Plastic and Reconstructive Surgery (top studies of the week, 22 November 2026): Directly compares graft options for alveolar cleft repair
Abstract
ObjectiveTo compare the safety and complication profiles of recombinant human bone morphogenetic protein (rhBMP-2) and iliac crest bone graft (ICBG) in alveolar cleft repair.DesignA systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and prospectively registered with PROSPERO (CRD420261340773).SettingPublished comparative studies identified through a comprehensive search of PubMed/MEDLINE, Embase and CENTRAL up to September 2026.Patients, Participants808 patients undergoing alveolar cleft repair, 395 with ICBG, 413 with rhBMP-2; across 7 studies (2 RCTs, 5 observational studies).InterventionsRhBMP-2 versus ICBG.Main Outcome MeasuresPrimary outcomes are graft failure, infection, oronasal fistula formation, postoperative swelling and wound dehiscence; secondary outcomes were operative time, length of stay and cost.ResultsSeven studies were included in the analysis. There were no statistically significant differences observed in graft failure (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.43-1.71, P = 0.67), wound dehiscence (OR = 1.33; 0.57-3.14) and fistula formation (OR = 0.46; 0.04-5.05). RhBMP-2 was associated with lower postoperative infection rates (OR = 0.20; 0.05-0.72; P = 0.01), although it was also associated with higher postoperative swelling (OR = 9.74, 95% CI 3.91-24.27, P < 0.00001). However, certainty of the evidence remained low.ConclusionsAlthough rhBMP-2 may be associated with lower infection rates, the increased postoperative swelling risk remains a concern. The limited number of studies, predominantly observational evidence, imprecision and heterogeneity limit the interpretation of these findings. Adequately powered RCTs are needed to establish the safety of rhBMP-2 relative to ICBG.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.